In Canada, patients with esophageal cancer have a 5-year survival rate of only 14%, the 2 nd worst in 2017. Esophageal squamous cell carcinoma (ESCC) is the most common esophageal cancer worldwide. Risk factors include tobacco smoking, alcohol use and esophagitis. Esophagitis is developed upon several insults (e.g. acid/bile reflux, radiation, infection). Epithelial damages typically trigger activation of stem cells which will orchestrate tissue regeneration. The existence of esophageal stem cells remained controversial until our studies. We recently identified that Krt15 promotor marks a subpopulation of esophageal basal cells which display self-renewal and multipotent capacities, characteristics consistent with a stem cell population. Our preliminary results suggest that Krt15 esophageal cells have tumorinitiating capacities in mouse. However, we still ignore the role of these cells at later stages of the disease. Cancer stem cells (CSCs) have been linked to treatment resistance and poor survival rate. Therefore, the characterization of esophageal CSCs is a promising strategy to improve survival and treatment in ESCC patients. Aims: The aim of this study is to investigate the role of Krt15+ esophageal cancer cells in cancer initiation, progression and relapse. We hypothesize that Krt15+ cells initiate tumor formation and contribute to the establishment of treatment resistance in ESCC patients. Methods: The carcinogen 4-nitroquinoline 1-ozide (4NQO) is used to induce oralesophageal lesions in mouse that morphologically resemble human ESCC. Krt15-CrePR1;Rosa26 mTomato/mGFP mice are treated with 4-NQO in the drinking water and expansion of Krt15+ (GFP-labeled) cells was measured. Results: To determine the role of Krt15+ cells in esophageal tumor initiation, we treated Krt15-CrePR1;Rosa26 mTomato/mGFP mice with 4-NQO. We observed that Krt15+ cells expand in the esophageal lesions. The clones formed by Krt15+ cells (GFP-labeled) were bigger in mice treated with 4-NQO than in control mice suggesting that Krt15+ cells contribute to ESCC expansion. Interestingly, in human ESCC tumors, we observed that K15 expression is localized at the tumor migration edges suggesting a role for K15 in migration and invasion. Furthermore, we isolated esophageal tumors from WT mice treated with 4-NQO. We observed that K15 expression is also increased in the invasive front of mouse
esophageal tumors. Finally, we quantified the expression of Krt15 transcript in mouse ESCC cell lines which harbor variable tumorigenicity and aggressiveness. We observed that Krt15 expression correlated with the aggressiveness of ESCC mouse cell lines. Conclusions: Our results support that Krt15+ stem cells play a role in ESCC initiation and progression suggesting that targeting these stem cells might be a therapeutic approach to improve survival of ESCC patients.
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